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Abstract 
   BACKGROUND: Preoperative embolization has the potential to decrease intraoperative blood 
loss and facilitate spinal cord decompression and tumor resection .  OBJECTIVE: We report our 
institutional experience with the embolization of hypervascular extradural spinal tumors with 
Onyx as well as earlier embolic agents in a series of 28 patients.  METHODS: A retrospective 
case review was conducted on patients undergoing preoperative transarterial embolization of a 
spinal tumor between 1995 and 2012 at our institution.  RESULTS: 28 patients met the inclusion 
criteria, with a mean age of 60.6 years. Twenty-eight patients had metastatic tumors.  In 14 
(50%) patients the metastases were from renal cell carcinomas.  54 vessels were embolized using 
PVA, NBCA, Onyx, coils, or embospheres.  Sixteen patients were treated with Onyx, 6 patients 
with PVA, 3 patients with embospheres, 2 patients with NBCA, and 3 patients with a 
combination of embolic agents.  The average decrease in tumor blush was 97.8% with Onyx 
versus 92.7% with the rest of the embolic agents (p=0.08).  The estimated blood loss was 1616 
ml (range 350-5000 ml).  Blood loss was 750 cc on average with Onyx versus 1844 with the rest 
of the embolic agents (p=0.14). The mean length of stay was 16 days.  The mortality rate was 
zero.  Pre- and post-operative modified Rankin Score (mRS) did not differ significantly in the 
series (3.12 vs. 3.10, respectively, p=0.9).  CONCLUSION: In our experience, the use of 
transarterial tumor embolization as an adjunct for spinal surgery is a safe and feasible option.   
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Introduction 
It is estimated that as many as 10% of cancer patients develop spinal metastases during 
the course of their disease.[1]  The goal of surgical treatment of symptomatic metastatic lesions 
is to improve the quality of life, preserve neurological function, achieve mechanical spinal 
stability, and in some cases provide diagnostic tissue for further treatment.  Surgery in patients 
with hypervascular spinal tumors (primary or metastatic) can be complicated by significant 
intraoperative bleeding.  Preoperative embolization has the potential to decrease intraoperative 
blood loss and facilitate spinal cord decompression and tumor resection.[2-10] A variety of 
liquid embolic agents have been utilized for presurgical tumor embolization, most frequently 
polyvinyl alcohol (PVA).  More recently, Onyx has emerged as a highly efficient agent for 
treatment of intracranial and spinal arteriovenous malformations and fistulas.[11] Its use for 
embolization of spinal tumors, however, has been very limited.  In this study, we report our 
institutional experience with the embolization of hypervascular extradural spinal tumors with 
several embolic agents in a series of 28 patients.  We highlight the safe and effective use of Onyx 
for spinal tumor embolization. 
 
 
Methods 
 Institutional review board approval was obtained prior to data collection. A retrospective 
case review was conducted on consecutive patients who underwent preoperative transarterial 
embolization of a spinal tumor between 1995 and 2012 at our institution. Patients with intradural 
tumors were excluded from the study.  Patients were selected for pre-operative embolization 
based on preoperative consensus of the senior spine surgeons for findings considered high-risk 
for intraoperative hemorrhage: known tumor histology (renal cell carcinoma, thyroid, melanoma)  
or pre-operative MRI findings of hypervascularity (flow voids, bright contrast enhancement, 
intratumoral hemorrhage).  Aggressive hemangiomas treated operatively for neurological deficits 
were also included given the high risk for catastrophic intraoperative blood loss.  All of the 
hypervascular tumors defined above were then evaluated angiogaphically for further diagnostic 
purposes or, potential embolization. 
Angiographic Technique 
Ghobrial 4 
 
 All procedures were performed through the transfemoral route under general anesthesia 
and somatosensory evoked monitoring.  Patients were heparinized and activated clotting time 
was maintained at 2 times the patient’s baseline intraoperatively.  The angiographic technique 
has been described previously.[12]  A 6 French groin sheath is introduced into the femoral 
artery, followed by a H1H spinal catheter or a Cobra 2 catheter (Cordis Corp. Bridgewater, NJ).  
Aortography is undertaken and selective bilateral catheterization of the corresponding segmental 
arteries (including 2 levels above and below the lesion) is performed. Spinal cord supply, tumor 
feeding pedicles, and the presence of normal en passage vessels are carefully evaluated.  
Depending on the conformation and origin of the feeder artery, various preshaped 5F catheters 
are selected for superselective catheterization  including SL10 (Boston Scientific, Natick, MA), 
echelon 10 (EV3, Plymouth, MN) and  marathon EV3 (EV3, Plymouth, MN).  
 
Embolization Technique 
Through a superselectively introduced microcatheter, a direct infusion of polyvinyl 
alcohol (PVA), n-butyl cyanoacrylate (NBCA), embospheres, or Onyx was performed into the 
branch supplying the tumor.  Flow control techniques were often utilized with PVA to make 
particles flow preferentially into the feeding branches of the tumors, rather than normal tissue. A 
repeat angiogram was obtained immediately after embolization in all cases to verify the changes 
in tumor blood flow. 
Multiple formulations of Onyx are available in the United States for clinical use.  In this 
study, the low-viscosity agent, Onyx 18, was utilized for most spinal embolizations as it allows 
for better penetration of the tumor vasculature.  Onyx-18 is composed of 6% ethylene vinyl 
alcohol copolymer and 94% DMSO.[13] The feeding artery was superselectively catheterized 
with an Echelon 10 (EV3 Endovascular, inc., Plymouth, MN) microcatheter or Marathon 
Catheter, as stated above.  The microcatheter was then flushed with normal saline, followed by 
dimethylsulfoxide (DMSO).  Next, Onyx was injected until adequate penetration of the tumor 
was achieved (Figure 1).  A percent obliteration of the tumor blush was obtained from each 
operative report dictated, as well as preoperative and postoperative percent change of 
angiographic nidus blush. 
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Spinal Surgery 
 
 Surgical interventions in all cases were performed within twenty four hours, typically, on 
the day following the embolization.  The goals of surgery were spinal cord decompression, tissue 
diagnosis, and restoration of spinal alignment and stability.  This was performed most commonly 
through the posterior approach, or alternatively through anterior or combined anterior-posterior 
approaches.  Intra-operative blood loss was estimated by the anesthesiologist.  
 
Complications 
 Procedural complications were defined as an adverse event prolonging hospital stay, or 
readmission within sixty days for a reason felt by the senior authors to be attributed to procedural 
technique.  This data was collected via a retrospective analysis of electronic medical records and 
were defined as retroperitoneal hematoma, femoral arterial pseudoaneurysm, stroke, myocardial 
infarction, pulmonary embolism, ileus, arterial dissection, and bleeding at the site of puncture.  
Additionally, all other complications not attributed to endovascular embolization, such as those 
due to the morbidity of metastatic disease and decompression spinal fusion surgery were 
recorded, as well as the hospital length of stay. 
Intraoperative blood loss was pulled from anesthesiologist records.  Final pathologist 
reports were pulled from electronic records.  Data on contrast usage, type and volume of 
embolization material, the number of embolized segmental vessels were recorded from 
intraoperative surgeon reports.  Lastly, the percent obliteration as estimated by decrease in the 
tumor blush as observed by the endovascular neurosurgeon was reported from operative notes.  
Specific patient data mentioned above on the use of Onyx embolysate was then compared 
directly to patients who had been treated with earlier embolization materials. 
 
Follow-up 
 Patient follow-up data was evaluated from electronic medical records.  The most recent 
follow-up visit within ninety days of admission was evaluated for neurologic improvement and 
functional status.  
Statistical Analysis 
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Statistical analysis was undertaken for the treatment groups via a software package (JMP 
statistical software, edition 9, www.jmp.com) with a Wilcoxon Rank Sum Test.  Statistical 
significance was defined as a P value of < 0.05. 
 
 
Results 
 There were thirty consecutive embolization patients who had met the criteria for the 
study, and all thirty were included (Table 1).  There were 14 women and 14 men with a mean 
age of 60.8 years. Twenty-eight patients had metastatic tumors.  In 14 (50%) patients the 
metastases were from renal cell carcinomas.  Table One illustrates the baseline characteristics of 
the patient population.  A total of 54 vessels were embolized using PVA, NBCA, Onyx, coils, or 
embospheres.  Sixteen patients were treated with Onyx, 6 patients with PVA, 3 patients with 
embospheres, 2 patients with NBCA, and 3 patients with a combination of embolic agents.    The 
mean volume of iodinated contrast used during the procedure was 164 milliliters (mL). The 
number of vessels embolized per patient was 1.8 on average. The total volume of Onyx used was 
1.86 ml on average(Table 2). There were no periprocedural complications related to contrast 
administration or transarterial embolization.  Notably, There were two wound washouts during 
the same hospital stay, one revision of instrumentation, three thromboembolic events which were 
diagnosed during the postoperative course, and one post-op ileus (Table 3a).  Data on the 
average number of levels instrumented, presence of decompression, corpectomy, or 
circumferential fusion were recorded (Table 3b).  The mortality rate was zero.  Post 
embolization, the average tumor blush decrease as reported by the interventionalist was 95%, 
where available.  Specifically, the average decrease in tumor blush was 97.8% with Onyx versus 
92.7% with the rest of the embolic agents (p=0.08).  
 
After embolization, the spinal surgery estimated blood loss(EBL) was 1616 ml, (range 
350-5000 ml) although data on EBL was available for 16 of 28 patients (Table 3)  The median 
length of stay was 16 days, and the median pre-operative and post-operative modified Rankin 
Score (mRS) was 3.13 and 3.10, respectively (P=0.9).   
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Specifically, blood loss was 750 cc on average using Onyx embolysate versus 1844 with 
the older embolic agents (p=0.14). Also, the decrease in tumor blush, hospital length of stay, and 
post-operative mRS were not significantly different (Table 4).     
 
 
 
Discussion 
With an expanding role for surgical excision of spinal metastases and other aggressive 
pathologies, adjunctive measures are increasingly used to improve both the effectiveness and 
safety of the usually palliative procedure.  Around 60% of all spinal metastasis, 40% of benign 
spinal neoplasms, and 85% of malignant spinal lesions are reportedly hypervascular.[5]  
Endovascular embolization prior to surgical excision of these hypervascular lesions may help 
identify regional vascular supply of the spinal cord, decrease intraoperative blood loss, decrease 
local recurrence, and even provide palliative pain relief.  Hypervascular lesions can be encased 
by the regional arterial supply making surgical excision extremely difficult and risky without 
embolization.  Hypervascular lesions most often embolized are renal cell carcinomas, germ cell 
tumors, and thyroid carcinomas.[14]  At our center, consideration is given to preoperative 
embolization primarily for those spinal tumors that demonstrate avid enhancement on MR 
imaging or for patients who have a positive history of renal cell carcinoma.   In our study, we 
sought assess the role of presurgical embolization for the main purpose of reducing 
intraoperative blood loss to improve surgical outcomes. The safety and efficacy of different 
embolic agents are also compared, though the small number of patients precludes definitive 
conclusions in this regard. This is to our knowledge the largest experience to date with an Onyx 
comparison to earlier generations of embolic materials in adults for preoperative embolization of 
spinal tumors. 
We demonstrate in a series of thirty patients that endovascular preoperative embolization 
of extradural spinal tumors can be safely undertaken.  The morbidity attributed to embolization 
in our series was zero, which correlates with the low rate of technical complications reported in 
prior retrospective studies (Table 5).  There were three thromboembolic events which occurred 
after spinal surgery, greater than 48 hours after spinal embolization, and therefore were attributed 
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to the combined risk factors of spinal surgery and malignancy.  Nevertheless, complications may 
occur and include death, permanent neurologic deficits, arterial occlusions, and ischemia of 
surrounding tissues.  Prabhu et al found that 8.5% of patients experience complications related to 
embolization of renal cell carcinomas.[15]   Likewise, Vetter et al reported 2 postoperative brain 
stem infarctions in a series of 38 cervical spine embolizations.[10]  The risk of contrast 
nephropathy should also be considered in patients with renal cell carcinoma, and every effort 
should be made to minimize the volume of contrast injected in this group of patients. 
 The results of this study demonstrate that Onyx embolization of spinal tumors is safe and 
effective.  Furthermore, Onyx was associated with higher rates of angiographic obliteration and 
reduced intra-operative bleeding compared with other embolic agents, although the difference 
did not reach statistical significance.  One obstacle to comparing intra-operative blood loss was 
the variability in surgeon experience, levels operated, and the volume of tumor that was resected 
by the surgeon. Also, there is no way to compare the degree of hypervascularity on imaging and 
the actual interaoperative bleeding risk. 
The improved efficacy of embolization may be related to the inherent properties of Onyx 
that allow longer, slower, and more controlled injections with better penetration of the tumor 
vasculature. Also, Onyx has excellent surgical handling properties due to its black color, which 
facilitates manipulation and cauterization of blood vessels. In all patients who underwent Onyx 
embolization, there were no pulmonary embolisms, nor were there any post-operative events of 
neurologic decline to suggest distal Onyx migration. 
A growing body of evidence supports the hypothesis that preoperative embolization may 
decrease intra-operative blood loss.[16, 17]  In a series of 20 vertebral tumors preoperatively 
embolized by Guzman et al[17], a trend toward decreased blood loss and intraoperative time was 
demonstrated.  Kato et al[18], found the blood loss to be almost half (1128 ml to 520 ml) with 
the addition of preoperative embolization (with either coils, NBCA, or PVA) for thoracic 
metastatic epidural tumors in 20 patients.  Notably, percent embolization and time to surgery 
after devascularization were not significant factors affecting blood loss.  Taniguchi et al 
evaluated the effects of preoperative embolization on total en bloc spondylectomy for solitary 
spinal metastases and found that intraoperative blood loss as well as the amount of blood 
transfused were significantly lower after preoperative embolization. [19]  In another study, 
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Manke et al[4] found blood loss to be 1.2L in patients treated with preoperative embolization 
compared to 5L in non-embolized patients.   
More recently, Ashour and colleagues[20] demonstrate the safe and effective use of Onyx 
in the pediatric population, embolizing 21 spinal lesions of tumor and vascular etiology.  
Elhamaddy et al[21] also has expanded the technique of head and neck tumor treatment by 
demonstrating that direct tumor puncture with onyx preoperatively with a mean tumor 
devascularization of 87%. 
 
A limitation of this study is the lack of a control group that did not undergo presurgical 
embolization.  Given the high risk of catastrophic blood loss from hypervascular tumors, a true 
control group with similar histologies would be difficult to obtain for this cohort.  Given the high 
risk of catastrophic blood loss from these lesions, there are no matched controls to provide a 
comparison of the blood loss.  Furthermore, given the relatively small population of patients 
undergoing embolization, subgroup analysis is difficult.  A trend towards lower blood loss was 
noted with the Onyx group, but does not account for the high variability in the levels fused, 
circumferential decompression, extent of angiographic obliteration, and perioperative 
hypervascularity on imaging (Table 3b).  One additional consideration regarding blood loss is the 
lack of data available for half of the study population.  This variability, as well as the broad range 
of tumor pathologies should be kept in mind when drawing conclusions about the efficacy in 
reducing intraoperative blood loss.   
Regardless of the technique, however, presurgical embolization appears to have an 
excellent safety profile.  While a number of aforementioned papers demonstrate the safety and 
benefit of decreased intraoperative blood loss with the use of preoperative embolization, a 
recently published univariate analysis of sixty-two patients with prior preoperative embolization 
and tumor resection did not find tumor vascularity as a significant factor affecting blood 
loss.[22]  Kobayashi and colleagues found the tumor volume, the invasiveness of the planned 
procedure, as well as the approach to be significant factors.  Multivariate analysis only showed 
the extent of the surgical procedure to be the only significant factor, while tumor characteristics 
such as the vascularity, histology, and particulars of embolization to be not statistically 
significant.[22]  Robial and colleagues, in a retrospective review of microsphere preoperative 
Ghobrial 10 
 
embolization for metastatic tumor, found no difference in blood loss regardless of embolization.  
Instead, the deciding factor was the extent of the procedure, specifically, whether or not a 
vertebrectomy was performed.[23]  Elhammady et al[24] followed forty-three patients embolized 
with Onyx alone, fourteen of which underwent a direct tumor puncture and embolization.  They 
conclude that direct tumor puncture might be the best way to penetrate the blood-barrier in order 
to limit blood loss.  Given the variability in the pathologies, as well as the method of delivery of 
Onyx, little can be inferred regarding the transarterial route alone as well as the effectiveness for 
spinal pathologies.  Still, these findings are intriguing given the growing body of evidence in 
support of decreasing blood loss, and warrant further investigation with randomized controlled 
studies.   
 
 
 
 
Conclusion 
 
 In our experience, the use of transarterial tumor embolization with Onyx as an adjunct for 
spinal surgery is a feasible alternative.  Larger prospective studies with matched controls are 
needed to make determinations of the efficacy of this intervention.  This could translate into 
reduced intra-operative blood loss and improved surgical results.   
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Figure 1.  56 year-old male with a history of mid-back pain and ataxia. (a) MRI T1-weighted 
imaging of the thoracic spine, post-gadolinium, sagittal view, demonstrating an enhancing 
paraspinal mass with invasion into posterior elements of thoracic spine with spinal cord 
compression. (b) Digital Subtraction Angiography (DSA), selective T7 microcatheter injection 
demonstrating tumor blush.  (c) DSA demonstrating decreased tumor filling after particle 
embolization.  (d) MRI T1-weighted imaging, post-gadolinium, sagittal view, demonstrating no 
residual mass after staged embolization and surgical decompression and fusion.  
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Table 1: Baseline Patient Characteristics 
 
Patient Age Gender Metastasis Cell type 
1 53 F Y nasopharyngeal CA 
2 59 F Y Carcinoma, indet. 
3 60 F Y thyroid CA 
4 57 F Y renal cell CA 
5 49 F Y plasmacytoma 
6 80 M Y hemangioblastoma 
7 41 M Y renal cell CA 
8 55 M Y renal cell CA 
9 71 M Y renal cell CA 
10 68 M Y NSCLC 
11 65 M Y NSCLC 
12 68 F Y renal cell CA 
13 64 F Y thyroid CA 
14 67 F Y renal cell CA 
15 83 F Y renal cell CA 
16 70 M Y Carcinoma, indet. 
17 48 F Y Carcinoma, indet. 
18 58 F Y hemangiopericytoma 
19 40 M Y paraganglioma 
20 66 F Y renal cell CA 
21 52 F Y Carcinoma, indet. 
22 71 F Y Carcinoma, indet. 
23 42 M Y renal cell CA 
24 70 M Y renal cell CA 
25 54 M Y renal cell CA 
26 60 M Y renal cell CA 
27 64 M Y renal cell CA 
28 65 M Y renal cell CA 
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Table 2.  Spinal Embolization Procedural Characteristics 
 
Patient Age Gender Pathology Embolic agent 
Segments 
embolized 
Contrast(mL) Estimated 
Obliteration(%) 
1 53 F nasopharyngeal CA NBCA 2 
100 100 
2 59 F Carcinoma, indet. onyx-18 1 
n/a n/a 
3 60 F thyroid CA onyx-34, onyx-18 2 
250 100 
4 57 F renal cell CA onyx-18 1 
n/a 100 
5 49 F plasmacytoma onyx-18 1 
n/a 100 
6 80 M hemangioblastoma onyx-34 1 
250 95 
7 41 M renal cell CA onyx-18 1 
150 90 
8 55 M renal cell CA onyx-18 1 
100 n/a 
9 71 M renal cell CA onyx-18,  coils 2 
200 95 
10 68 M NSCLC onyx-18 1 
100 100 
11 65 M NSCLC NBCA 1 
140 100 
12 68 F renal cell CA onyx-18 3 
120 100 
13 64 F thyroid CA onyx-18 4 
200 90 
14 67 F renal cell CA Polyvinyl alcohol 2 
300 95 
15 83 F renal cell CA Polyvinyl alcohol 1 
190 100 
16 70 M Carcinoma, indet. 
Polyvinyl alcohol, 
 coils, embospheres 2 
210 75 
17 48 F Carcinoma, indet. Polyvinyl alcohol 1 
227 75 
18 58 F hemangiopericytoma 
Polyvinyl alcohol, 
 coils, embospheres 2 
350 75 
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19 40 M paraganglioma Polyvinyl alcohol 4 
147 100 
20 66 F renal cell CA embospheres 2 
n/a 100 
21 52 F Carcinoma, indet. embospheres 1 
n/a 100 
22 71 F Carcinoma, indet. embospheres 2 
210 95 
23 42 M renal cell CA onyx-18 1 
n/a n/a 
24 70 M renal cell CA onyx-18 2 
110 100 
25 54 M renal cell CA onyx-18 3 
100 100 
26 60 M renal cell CA Polyvinyl alcohol 1 
100 100 
27 64 M renal cell CA onyx-18 2 
n/a n/a 
28 65 M renal cell CA onyx-18 4 
300 100 
 
 
Table 3A.  Surgical Outcomes Summary 
 
Patien
t Age 
Gende
r Pathology 
LO
S 
(d) 
Complication EBL(cc
) 
PreO
p 
mRS 
PostO
p mRS 
1 53 F nasopharyngeal CA 
7 N n/a 4 4 
2 59 F Carcinoma, indet. 
17 
aortoiliac 
thrombosis n/a 2 2 
3 60 F thyroid CA 
11 N n/a 4 4 
4 57 F renal cell CA 
50 
Pulmonary 
embolism n/a 4 4 
5 49 F plasmacytoma 
10 N n/a 5 5 
6 80 M hemangioblastoma 
8 N 350 5 5 
7 41 M renal cell CA 
7 N n/a 4 4 
Ghobrial 17 
 
8 55 M renal cell CA 
21 N n/a 4 4 
9 71 M renal cell CA 
16 N n/a 3 3 
10 68 M NSCLC 
28 
Pulmonary 
embolism n/a 5 5 
11 65 M NSCLC 
55 N n/a 3 3 
12 68 F renal cell CA 
16 N 1700 4 4 
13 64 F thyroid CA 
23 
Respiratory 
Failure n/a 2 2 
14 67 F renal cell CA 
13 iliac vein repair 1000 4 4 
15 83 F renal cell CA 
16 acute renal 
failure, 
urosepsis 500 4 4 
16 70 M Carcinoma, indet. 
16 
revision of 
instrumentatio
n 1800 4 4 
17 48 F Carcinoma, indet. 
13 N 2000 3 2 
18 58 F 
hemangiopericytom
a 
34 
Surgical site 
infection 3500 4 4 
19 40 M paraganglioma 
28 N 1700 4 3 
20 66 F renal cell CA 
8 N 900 4 4 
21 52 F Carcinoma, indet. 
5 N 1000 1 1 
22 71 F Carcinoma, indet. 
15 
hardware 
failure 3700 3 3 
23 42 M renal cell CA 
23 
Surgical site 
infection 700 4 4 
24 70 M renal cell CA 
8 N 500 4 4 
25 54 M renal cell CA 
10 
wound 
450 1 1 
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infection 
26 60 M renal cell CA 
8 
 
N n/a 3 3 
27 64 M renal cell CA 
8 N n/a 4 4 
28 65 M renal cell CA 
8 N n/a 3 5 
 
Table 3b. Selected Surgical Details 
 
Patient Age Gender Pathology 
LOS 
(d) 
Spinal 
decompression? 
Circumferential 
(anterior/posterior)? 
Corpectomy 
(partial, en-
bloc?) 
EBL(cc) Levels 
Instrumented, 
n 
1 53 F nasopharyngeal CA 
7 N yes Partial n/a 9 
2 59 F Carcinoma, indet. 
17 Y yes Partial n/a 7 
3 60 F thyroid CA 
11 Y yes Partial n/a 7 
4 57 F renal cell CA 
50 Y n/a n/a n/a n/a 
5 49 F plasmacytoma 
10 Y no n/a n/a 9 
6 80 M hemangioblastoma 
8 Y no n/a 350 4 
7 41 M renal cell CA 
7 N yes Partial n/a 3 
8 55 M renal cell CA 
21 Y yes Partial n/a 4 
9 71 M renal cell CA 
16 Y yes Partial n/a 4 
10 68 M NSCLC 
28 Y yes Partial n/a 8 
11 65 M NSCLC 
55 N no n/a n/a 8 
12 68 F renal cell CA 
16 Y 
no Partial, 
lateral 
extracavitary 1700 8 
13 64 F thyroid CA 
23 Y 
no Partial, 
lateral 
extracavitary n/a 12 
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14 67 F renal cell CA 
13 Y Yes Partial 1000 3 
15 83 F renal cell CA 
16 Y No n/a 500 10 
16 70 M Carcinoma, indet. 
16 Y No 
b/a 
1800 9 
17 48 F Carcinoma, indet. 
13 Y No n/a 2000 9 
18 58 F hemangiopericytoma 
34 Y No n/a 3500 8 
19 40 M paraganglioma 
28 Y Yes Partial 1700 9 
20 66 F renal cell CA 
8 Y Yes Partial 900 6 
21 52 F Carcinoma, indet. 
5 Y Yes Partial 1000 3 
22 71 F Carcinoma, indet. 
15 Y Yes Partial 3700 7 
23 42 M renal cell CA 
23 Y No n/a 700 6 
24 70 M renal cell CA 
8 Y 
No Partial- 
lateral 
extracavitary 500 7 
25 54 M renal cell CA 
10 Y No n/a 450 8 
26 60 M renal cell CA 
8 
 
Y No n/a n/a n/a 
27 64 M renal cell CA 
8 N No n/a n/a n/a 
28 65 M renal cell CA 
8 Y No n/a n/a 5 
 
Table 4.  Onyx Embolization Characteristics 
Embolization 
Agent 
Onyx  Other  p-value 
N 16 12 P > 0.05 
Median Decrease 
in Tumor Blush  
97.8% 92.7% P = 0.08 
Median Surgical 
EBL 
750 1844 P = 0.14 
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Median LOS (d) 17.4 15.9 P = 0.38 
Median Pre-
operative mRS 
3.47 3.77 P = 0.36 
Median Post-
operative mRS 
3.58 4.00 P = 0.09 
 
Table 5: Previous selected series of presurgical embolization 
 
 
Autho
rs N 
mea
n 
age 
Metast
atic? 
(%) 
Embolizat
ion 
Method 
cervi
cal(
%) 
thora
cic(%
) 
lumb
ar(%
) 
Compl
ication
? 
surger
y 
EBL 
(cc) 
Shi et 
al. 
1
8 42 16.7 
Polyvinyl 
Alcohol 33 61 6 0 
Decom
pressio
n 
fusion 1100 
Berkef
eld et 
al. 
5
9 54.2 78 
particle/coi
l 6 43 51 
1- 
transie
nt leg  
weakne
ss 
corpect
omy 
4350 
-
contr
ol 
1850 
-
partic
le/coil
s 
1800 
-
partic
les 
only 
Wilson 
et al. 
1
0
0 54 71 
Polyvinyl 
Alcohol 35 20 65 
1-acute 
stroke 
ant 
13/post 
42 
combin
ed 45 
1562 
-
prima
ry 
1652 
-non-
RCC  
2856 
-RCC  
Gore et 
al. 
1
0 33.5 40 Onyx 10 10 40 0 
Decom
pressio
n 
fusion n/a 
Vetter 3 57 60 PVA/coils/ 100 0 0 0 corpect 2500 
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et al. 8 gel foam omy 
Nader 
et al. 
1
0 58 50 
PVA/coils/ 
gel foam 0 50 50 
1-
parapar
esis 
corpect
omy 2800 
Manke 
et al. 
1
7 64 100 
Polyvinyl 
Alcohol 18 54 27 0 
corpect
omy 
5000 
-
contr
ol 
1500 
-RCC 
 
 
 
 
